Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5942
    +0.0005 (+0.08%)
     
  • NZD/EUR

    0.5549
    +0.0003 (+0.05%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.68
    -0.13 (-0.16%)
     
  • GOLD

    2,328.10
    -10.30 (-0.44%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,460.08
    0.00 (0.00%)
     
  • NZD/JPY

    92.2220
    +0.1070 (+0.12%)
     

3 Things About Moderna That Smart Investors Know

Prior to the pandemic, Moderna (NASDAQ: MRNA) was like many other small biotechs. In fact, for the full year of 2019, Moderna had only $60 million in revenue, entirely from collaborations and grants, and it posted a net loss of $514 million. As we know, Moderna's ability to rapidly produce a vaccine for the COVID-19 virus changed the financial prospects for the company and put it in a completely different position today.